Anthony Cirrincione, PhD

Postdoctoral Associate in Computational Oncology at the Myeloma Institute at @SylvesterCancer

[Francesco Maura @FrancescoMaura4]

New paper out today in @BloodJournal from the fantastic collaboration between @HeidelbergU @HDMyeloma @univmiami @MSKCancerCenter 🎉. Paper title: "The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma" #msmm (1/x)

[VJHemOnc @VJHemOnc]

Wonderful speaking with @FrancescoMaura4 from @SylvesterCancer who is at #ASH23 sharing findings illustrating distinct temporal patterns in the acquisition of early genomic drivers in #MultipleMyeloma

More to come soon on https://t.co/Vqyt4afDXd 👀

@ASH_hematology #Myeloma #MMsm

[Francesco Maura @FrancescoMaura4]

@BachisioZic presenting our new data focused on how myeloma cells and immune system promote resistance to daratumumab #mmsm #ASH23 #wgs @SylvesterCancer @unito. Full study available on @medrxivpreprint (link below)

[nizar jacques bahlis @NBahlis]

Amazing work by ⁦@MKaddouraMD⁩ and ⁦@FrancescoMaura4⁩ defining the molecular time clock and genomic events in myeloma #ASF23

[Francesco Maura @FrancescoMaura4]

👇👇👇 the highlights the importance to comprehensively profile smoldering patients enrolled in intervention trials
#mmsm kudos to @BenDiamondMD for this important work. @SylvesterCancer @DrOlaLandgren @dikokaz #ASH2023

[Malin Hultcrantz MD PhD @MalinHultcrantz]

Great work on genomic profiling of SMM @BenDiamondMD #ASH23 #mmsm

[Francesco Maura @FrancescoMaura4]

Final oral from the lab for #ASH23 @cirriant is presenting impact of pre and post gain deletions in multiple myeloma across >1000 whole genomes! #mmsm another great collaborative effort with @HDMyeloma @MSKCancerCenter @SylvesterCancer @univmiami

[C. Ola Landgren, M.D. @DrOlaLandgren]

Dr Anthony Cirrincione @cirriant will present data revealing novel mechanisms underlying inactivation of tumor suppressor genes on duplicated chromosomes in multiple myeloma
https://t.co/BwVelNHC7U

@francescomaura4 #mmsm #ASH23

[C. Ola Landgren, M.D. @DrOlaLandgren]

@DrOlaLandgren will present long-term followup data from the daratumumab monotherapy Phase 2 Centaurus study
https://t.co/U89zhplp9Q

@EagleMyeloma #mmsm #ASH23

[C. Ola Landgren, M.D. @DrOlaLandgren]

Dr Ben Diamond @BenDiamondMD will present on genomic profiling to interpret the outcomes of early intervention for high-risk smoldering myeloma
https://t.co/5UJLpIcBt2

@dikokaz #mmsm #ASH23

[C. Ola Landgren, M.D. @DrOlaLandgren]

Dr Marios Papadimitriou will present on the genomic and transcriptomic landscape of hyper-APOBEC multiple myeloma
https://t.co/3RsEigM8tl

@francescomaura4 #mmsm #ASH23

[C. Ola Landgren, M.D. @DrOlaLandgren]

Dr Marcella Kaddoura will present on the temporal evolution of chromosome 1q gain and hyperdiploidy and its impact on clinical outcomes in multiple myeloma
https://t.co/1XQaglB125

@francescomaura4 #mmsm #ASH23

[C. Ola Landgren, M.D. @DrOlaLandgren]

See you soon at #ASH23 in San Diego!

@theMMRF @IMFmyeloma @HealthtreeMM @LLSusa @ASH_hematology @SylvesterCancer @univmiami #mmsm #miami @NIH @theNCI @JanssenUS @pfizer @bmsnews @SanofiUS @Amgen @Karyopharm @abbvie @TakedaOncology @genentech @Regeneron

[C. Ola Landgren, M.D. @DrOlaLandgren]

At #ASH23 in San Diego in Dec 2023, the Myeloma Institute at Univ of Miami will give several oral presentations and participate in many collaborative myeloma talks.
Congrats to everybody who has contributed. Here is a list of presenters and topics, as well as links to abstract:

[Anthony Cirrincione, PhD @cirriant]

Looking forward to presenting our latest findings and representing our team!

[C. Ola Landgren, M.D. @DrOlaLandgren]

Dr Anthony Cirrincione @cirriant will present data revealing novel mechanisms underlying inactivation of tumor suppressor genes on duplicated chromosomes in multiple myeloma
https://t.co/BwVelNHC7U

@francescomaura4 #mmsm #ASH23

[VJHemOnc @VJHemOnc]

#IMS23 | Another great interview with Anthony Cirrincione (@SylvesterCancer) who spoke on the earliest genomic events in multiple myeloma & the importance of understanding the genomic landscape of this disease.

@Myeloma_Society #MMsm #HemOnc #IMS2023

[Anthony Cirrincione, PhD @cirriant]

Thank you very much @DrOlaLandgren for all your continued leadership and support! I am very proud to be a part of such an amazing team 🙏

[C. Ola Landgren, M.D. @DrOlaLandgren]

Today, Anthony Cirrincione, PhD from Myeloma Division in Miami gave a great talk at #IMS23 meeting. Novel insights on pre- & post-gain deletions, and how they play a role in myeloma and its prognosis

@cirriant #mmsm @SylvesterCancer @IMFmyeloma @theMMRF @HealthtreeMM @LLSusa

[C. Ola Landgren, M.D. @DrOlaLandgren]

The Myeloma Research Institute at Univ of Miami has a world-class COMPUTATIONAL ONCOLOGY lab focusing on myeloma.

We are a global leader in drug development & we provide cutting-edge clinical care. Come join us!

#mmsm
@IMFmyeloma
@theMMRF
@HealthtreeMM
@SylvesterCancer
#IMS23

[Anthony Cirrincione, PhD @cirriant]

@FrancescoMaura4 @HDMyeloma @MSKCancerCenter @SylvesterCancer Thank you and the rest of the team for all your guidance and support that made this possible 🙏

[Anthony Cirrincione, PhD @cirriant]

Thank you very much for all your support @FrancescoMaura4, our myeloma genomics lab, and our collaborators! #IMS2023

[Francesco Maura @FrancescoMaura4]

Anthony Cirrincione from our lab presented the concept of pre- and post-gain deletions at #IMS23! Great collaborative effort with @HDMyeloma @MSKCancerCenter @SylvesterCancer